Summit Therapeutics (SMMT) Notes Payables (2021 - 2024)

Summit Therapeutics (SMMT) has reported Notes Payables for 4 consecutive years, with $24.5 million the latest figure, recorded in Q3 2024.

• Quarterly Notes Payables fell 75.5% year-over-year to $24.5 million in Q3 2024, while the trailing twelve-month figure through Sep 2024 was $24.5 million (down 75.5% YoY) and the FY2022 annual result came in at $19.8 million, changed N/A from the prior year.
• Notes Payables eased to $24.5 million in Q3 2024 per SMMT's latest filing, from $100.0 million in the prior quarter.
• Over the last five years, Notes Payables for SMMT reached as high as $100.0 million in Q3 2023 and fell as low as $19.8 million in Q4 2022.
• A 4-year average of $59.8 million and a median of $55.0 million in 2021 frame the typical range for Notes Payables.
• The largest YoY upside for Notes Payables was 75.5% in 2024 against a maximum downside of 75.5% in 2024.
• Year by year, Notes Payables stood at $55.0 million in 2021, then tumbled by 64.03% to $19.8 million in 2022, then soared by 405.82% to $100.0 million in 2023, then sank by 75.5% to $24.5 million in 2024.
• According to Business Quant data, Notes Payables over the past three periods registered $24.5 million, $100.0 million, and $100.0 million for Q3 2024, Q2 2024, and Q3 2023 respectively.